These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1363391)

  • 1. Intracavernous self-injection therapy for the treatment of erectile dysfunction.
    Chiang HS; Wen TC; Wu CC; Chiang WH
    J Formos Med Assoc; 1992 Sep; 91(9):898-901. PubMed ID: 1363391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
    Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Our experience with pharmacological erection treatment of erectile dysfunction.
    Hattat H; Ozkara H; Akkus E; Alici B
    J Androl; 1994; 15 Suppl():47S-49S. PubMed ID: 7721677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China.
    He L; Wen J; Jiang X; Chen H; Tang Y
    Andrologia; 2011 Jun; 43(3):208-12. PubMed ID: 21486416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
    Kunelius P; Lukkarinen O
    Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.
    Chen JK; Hwang TI; Yang CR
    Br J Urol; 1992 Apr; 69(4):404-7. PubMed ID: 1581812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of penile vascular effect induced by intracavernous injection of papaverine and prostaglandin E1.
    Hwang TI; Lue TF; Yang CR; Chang CL; Chang CH; Wu HC
    Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1038-41. PubMed ID: 2634727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence.
    Wang CJ; Wu CC; Huang CH; Chiang CP
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Nov; 8(11):585-90. PubMed ID: 1296038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.